Devextinetug

Last updated

Devextinetug
Clinical data
Other namesIXT-m200; Ch-mAb7F9; METH-mAb; Anti-methamphetamine chimeric monoclonal antibody; Anti-methamphetamine monoclonal antibody
Routes of
administration 		Intravenous injection [1]
Drug class Monoclonal antibody
Identifiers
PubChem SID
UNII

Devextinetug (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name; developmental code name IXT-m200) is a monoclonal antibody against methamphetamine which is under development for the treatment of substance-related disorders including methamphetamine overdose. [1] [2] [3] It is taken by intravenous injection. [1] The drug has been found to reduce the toxicity of methamphetamine in overdose, for instance reducing agitation and need for sedation. [2] Devextinetug is under development by InterveXion Therapeutics. [1] As of May 2024, it is in phase 2 clinical trials for substance-related disorders. [1]

See also

References

  1. 1 2 3 4 5 "InterveXion Therapeutics". AdisInsight. 28 May 2024. Retrieved 13 January 2026.
  2. 1 2 Kosten TR (May 2024). "Vaccines as Immunotherapies for Substance Use Disorders". The American Journal of Psychiatry. 181 (5): 362–371. doi:10.1176/appi.ajp.20230828. PMID   38706331. Drug overdoses from a mixture of opioids and methamphetamine increased over eightfold between 2012 and 2019 (2, 59). Like CUD, no pharmacotherapies or vaccines are FDA approved for methamphetamine, as many clinical trials have failed. Intervexion has completed a 20-patient randomized, multisite, open-label, phase 2 study comparing their methamphetamine monoclonal (devextinetug) to treatment-asusual in patients with mild to moderate methamphetamine toxicity. One hour after dosing, 50% of treated patients (versus 25% control subjects) showed normalization of agitation and fewer needed to be sedated (31.3% vs. 75.0%) (60).
  3. ↑ Berquist MD, Gunnell M, Henry R, Gentry WB, Stevens MW (December 2025). "Comparison between a chimeric anti-methamphetamine monoclonal antibody and humanized antibodies on pharmacological effects of methamphetamine". Psychopharmacology. doi:10.1007/s00213-025-06959-9. PMID   41384974.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.